Choroideremia(CHM) is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium and retina. This disease is caused by mutations in the X-linked CHM gene encoding a Ras-related GTPase Rab escort protein (REP)-1, which is extremely important for the retinal function. Choroideremia is characterized by extensive loss of all retinal layers in the eyes.
DelveInsight's, "Choroideremia Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Choroideremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight
Some of Choroideremia Companies are:*
Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight
DelveInsight's Choroideremia report covers around 50+ products under different phases of clinical development like*Late-stage products (Phase II and Phase II/III) *Mid-stage products (Phase II and Phase II/III) *Early-stage products (Phase I/II and Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates *Route of Administration
Choroideremia Key Products*4D-110 *RG 6367 *BIIB111 *Metformin *And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight
Current Choroideremia Treatment Scenario and Choroideremia Emerging Therapies:*How many companies are developing Choroideremia drugs? *How many Choroideremia drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Choroideremia? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Choroideremia therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for Choroideremia and their status? *What are the key designations that have been granted to the emerging drugs?
Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Choroideremia: Overview
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
Choroideremia - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Choroideremia Collaboration Deals
Late Stage Products (Phase III)
* Comparative Analysis
BIIB111: Biogen
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
* Comparative Analysis
4D110:
Drug profiles in the detailed report.....
Preclinical stage products
* Comparative Analysis
Metformin:
Drug profiles in the detailed report.....
Inactive Products
* Comparative Analysis
Choroideremia Key Companies
Choroideremia Key Products
Choroideremia- Unmet Needs
Choroideremia- Market Drivers and Barriers
Choroideremia- Future Perspectives and Conclusion
Choroideremia Analyst Views
Choroideremia Key Companies
Appendix
About DelveInsight
DelveInsight is a leading
Media Contact
Company
Contact Person:
Email: info@delveinsight.com
Phone: +19193216187
Address:
City: Albany
State:
Country:
Website: https://www.delveinsight.com/report-store/choroideremia-pipeline-insight
Source: www.abnewswire.com
.
(C) 2021 M2 COMMUNICATIONS, source